ArticleOphthalmology science
A Second-Generation (44-Channel) Suprachoroidal Retinal Prosthesis: A Single-Arm Clinical Trial of Feasibility.
Article in Ophthalmology science. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Second-Generation (44-Channel) Suprachoroidal Retinal Prosthesis: Surgical Stability and Safety During a 2-Year Clinical Trial.Clinical & experimental ophthalmology · 2025Trial
- Determinants of spatial resolution in retinal prostheses: understanding the gap between geometry and vision.Biomedical engineering letters · 2026Review
- Seeing anew: Mechanisms, outcomes, and challenges in adapting to restored sight via visual prostheses.Progress in retinal and eye research · 2026Review
- Neural Vision Restoration in Ophthalmology.Annals of biomedical engineering · 2026Review
- Patient Preferences for the PRIMA Retinal Prosthesis for Vision Restoration for Dry Age-Related Macular Degeneration: An International Survey Study.Translational vision science & technology · 2026Article
- A Dynamic Virtual Channel Approach to Enhance Retinal Prosthetic Precision.Biomimetics (Basel, Switzerland) · 2026Article
- Bilateral retinal implants for improving visual restoration: a simulated bionic vision study.Medical & biological engineering & computing · 2026Article
- Bionic vision technologies: progress and perspectives on retinal prostheses and optogenetics for the treatment of advanced retinal degeneration.Frontiers in medical technology · 2026Review
- Can bionic eyes restore vision? Breakthroughs, challenges, and future frontiers in ophthalmology - A comprehensive review.Journal of biological engineering · 2025Article
- Restoration of Sight with Electronic Retinal Prostheses.Annual review of vision science · 2025Review
- Development and Evaluation of Multi-Module Retinal Devices for Artificial Vision Applications.Micromachines · 2025Article
- Face and Available Chair Detection and Localization With a Second-Generation (44-Channel) Suprachoroidal Retinal Prosthesis.Translational vision science & technology · 2025Observational
- Inherited Retinal Degenerations and Non-Neovascular Age-Related Macular Degeneration: Progress and Unmet Needs.Translational vision science & technology · 2024Review
- Application of Silicone in Ophthalmology: A Review.Materials (Basel, Switzerland) · 2024Review
- Chronic electrical stimulation with a peripheral suprachoroidal retinal implant: a preclinical safety study of neuroprotective stimulation.Frontiers in cell and developmental biology · 2024Article
- Review of brain-computer interface technology in ophthalmology: Current status, challenges and future directions.Advances in ophthalmology practice and researchReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To assess the feasibility of a second-generation (44-channel) suprachoroidal retinal prosthesis for provision of functional vision in recipients with end-stage retinitis pigmentosa (RP) over 2.7 years. Design: Prospective, single-arm, unmasked interventional clinical trial. Participants: Four participants, with advanced RP and bare-light perception vision. Methods: The 44-channel suprachoroidal retinal prosthesis was implanted in the worse-seeing eye. Device stability, functionality, and adverse events were investigated at approximately 12-week intervals up to 140 weeks (2.7 years) postdevice activation. Main Outcome Measures: Serious adverse event (SAE) reporting, visual response outcomes, functional vision outcomes, and quality-of-life outcomes. Results: All 4 participants (aged 39-66 years, 3 males) were successfully implanted in 2018, and there were no device-related SAEs over the duration of the study. A mild postoperative subretinal hemorrhage was detected in 2 recipients, which cleared spontaneously within 2 weeks. OCT confirmed device stability and position under the macula. Improvements in localization abilities were demonstrated for all 4 participants in screen-based, tabletop, and orientation and mobility tasks. In addition, 3 of 4 participants recorded improvements in motion discrimination and 2 of 4 participants recorded substantial improvements in spatial discrimination and identification of tabletop objects. Participants reported their unsupervised use of the device included exploring new environments, detecting people, and safely navigating around obstacles. A positive effect of the implant on participants' daily lives in their local environments was confirmed by an orientation and mobility assessor and participant self-report. Emotional well-being was not impacted by device implantation or usage. Conclusions: The completed clinical study demonstrates that the suprachoroidal prosthesis raises no safety concerns and provides improvements in functional vision, activities of daily living, and observer-rated quality of life. Financial Disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.